Tiedoksi
Euroopan lääkevirasto (EMA) järjesti 26.10. CTIS-järjestelmää koskevan koulutustilaisuuden. Koulutustilaisuuden tallenne on nyt julkaistu (linkki alla).
Yst. terveisin, Katja
Dear Members of the CTIS Member States Group,
The CTIS Change Management team are pleased to share that a video recording of the virtual event 'Clinical Trials Information System (CTIS): The future user perspective', held on 26 October, is now available EMA’s corporate website:
Clinical Trials Information System (CTIS): Virtual information day | European Medicines Agency (europa.eu)https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-virtual-information-day
The purpose of this Information Day was to help future CTIS users prepare for submitting and evaluating clinical-trial applications in the system after its go-live on 31 January 2022. The virtual event, aimed mainly at clinical-trial sponsors and contract research organisations, was organised with support from the DIA and registered a high attendance.
Please feel free to share this announcement within your network.
Thank you.
On behalf of CTIS Change Management team
Kind regards,
Vasiliki (Vicky) Papaioannou CTIS Change Officer Data Analytics and Methods Task Force
European Medicines Agency Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands Telephone +31 (0)88 781 6972 vasiliki.papaioannou@ext.ema.europa.eumailto:vasiliki.papaioannou@ext.ema.europa.eu | www.ema.europa.euhttps://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.ema.europa.eu%2F&data=02%7C01%7C%7C75c4c9bf85a54d7fe76a08d74b192b6a%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C637060443778541585&sdata=v5Hn1D%2F86T34C5Wtz6ssyCYccI2rLR%2BzjSYy3LOB5SU%3D&reserved=0 | For directions, see How to find ushttps://www.ema.europa.eu/en/about-us/contact/how-find-us
This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this email, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this email in error, please inform the sender immediately.
Classified as public by the European Medicines Agency
________________________________________________________________________ This e-mail has been scanned for all known viruses by European Medicines Agency. ________________________________________________________________________